Clinical Trials Directory

Trials / Conditions / BRCA2 Mutation

BRCA2 Mutation

58 registered clinical trials studyying BRCA2 Mutation20 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingRandomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at Hi
NCT07499999
Dana-Farber Cancer InstitutePhase 2
RecruitingCognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene
NCT06817694
CHU de Quebec-Universite LavalN/A
RecruitingHormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
NCT06972719
Duke UniversityN/A
RecruitingBRCA Mutation Carriers' Platform a Multicenter Study
NCT07253051
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RecruitingEvaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Meta
NCT06201234
GBG Forschungs GmbHPhase 2
RecruitingPhase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-neg
NCT06488378
Dana-Farber Cancer InstitutePhase 1
RecruitingNovel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
NCT05485766
Okayama UniversityPhase 2
RecruitingA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519
858 Therapeutics, Inc.Phase 1 / Phase 2
RecruitingStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660
Acerand Therapeutics (Shanghai) LimitedPhase 1 / Phase 2
RecruitingOlaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
NCT06177171
Pamela MunsterPhase 1
WithdrawnChemo-free BRCA-targeted Neoadjuvant Strategy
NCT05209529
European Organisation for Research and Treatment of Cancer - EORTCPhase 2
RecruitingContribution of Oncogenetics in Breast Cancer in Reunion Epidemiology of Breast Cancer in Reunion: Study of th
NCT05898009
Centre Hospitalier Universitaire de la RéunionN/A
RecruitingCombination Therapy in Cancers With Mutations in DNA Repair Genes
NCT05694715
University of California, San FranciscoPhase 1
RecruitingStudy of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermedia
NCT05498272
Rana McKay, MDPhase 2
RecruitingAn Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk a
NCT05420064
Memorial Sloan Kettering Cancer CenterN/A
UnknownPilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy
NCT05448963
Chang Gung Memorial HospitalN/A
Active Not RecruitingLobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients
NCT05410951
European Institute of Oncology
UnknownLongitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
NCT05537844
Liz-Anne Lewsley
RecruitingFaCT Trial (Facilitated Cascade Testing Trial)
NCT04613440
Weill Medical College of Cornell UniversityN/A
Active Not RecruitingInterest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening
NCT04273542
Centre Jean PerrinN/A
TerminatedBrUOG 390: Neoadjuvant Treatment With Talazoparib
NCT04598321
Brown UniversityPhase 1
RecruitingSHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
NCT04150042
General Oncology, Inc.Phase 1
CompletedPromoting Men's Adherence to BRCA1/2 Germline Genetic Testing
NCT04683068
European Institute of OncologyN/A
CompletedA Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer
NCT04651920
Lei Li
UnknownEfficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian
NCT04556071
Xiaoxiang ChenPhase 2
UnknownAnlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
NCT04566952
Xiaoxiang ChenPhase 2
CompletedHOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Br
NCT03685331
Abramson Cancer Center at Penn MedicinePhase 1
CompletedSurgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction
NCT04108117
Severance Hospital
Enrolling By InvitationGenetic Education in BRCA Families
NCT03544983
Georgetown UniversityN/A
CompletedEvaluating Cascade Communication Methods
NCT04428736
University of Pennsylvania
RecruitingProstate Cancer Genetic Risk Evaluation and Screening Study
NCT05129605
Massachusetts General Hospital
CompletedProspective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM)
NCT04866992
University of Texas Southwestern Medical Center
UnknownHomologous Recombination Deficiency Status in Epithelial Ovarian Cancer
NCT04190667
Lei Li
SuspendedSurgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy
NCT04151368
University Health Network, TorontoN/A
Active Not RecruitingBRCA1/2 Flu Vaccine
NCT04499534
Abramson Cancer Center at Penn Medicine
CompletedWeb-based Family History Tool
NCT04890327
Weill Medical College of Cornell UniversityN/A
UnknownEfficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
NCT04055038
Blokhin's Russian Cancer Research CenterPhase 2 / Phase 3
RecruitingRegistry of Subjects at Risk of Pancreatic Cancer
NCT04095195
Associazione Italiana per lo Studio del Pancreas
UnknownHealth After eaRly Menopause Due to Oophorectomy
NCT03835793
The Netherlands Cancer Institute
TerminatedFunctional Analysis of BRCAness
NCT04780945
Leiden University Medical CenterPhase 2
CompletedThe Genetic Education for Men Trial: Web-Based Education vs. Standard Care
NCT02957981
Georgetown UniversityN/A
UnknownBRCA Main Home Nutritional Intervention-random Study
NCT03570125
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone PalermoN/A
UnknownAbbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing
NCT03475979
Seoul National University Hospital
CompletedDecision Support for BRCA Testing in Ethnically Diverse Women
NCT03470402
Columbia UniversityN/A
Active Not RecruitingBRCA Founder OutReach (BFOR) Study
NCT03351803
Memorial Sloan Kettering Cancer Center
CompletedDepression and Body Image Distress Following Mastectomy With Reconstruction
NCT03428399
Massachusetts General Hospital
WithdrawnCombination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
NCT03032614
The University of Texas Health Science Center at San AntonioPhase 2
RecruitingLiquid Biopsy Evaluation and Repository Development at Princess Margaret
NCT03702309
University Health Network, Toronto
CompletedIMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)
NCT04012229
Centre Hospitalier Universitaire de Besancon
CompletedManagement of Women With BRCA1/2 Mutation
NCT03211611
University Hospital, Montpellier
CompletedMagnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast Cancer
NCT03684733
Royal Marsden NHS Foundation Trust
CompletedPre-Salpingo-Oophorectomy Pilot Study of MAKO 7 Device Performance
NCT02974842
nVision Medical
CompletedUse of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers
NCT03495609
University Hospital, GhentPhase 4
CompletedDietary Intervention and BRCA Penetrance
NCT03066856
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoN/A
CompletedBotulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction
NCT01591746
Mayo ClinicPhase 3
Active Not RecruitingRadical Fimbriectomy for Young BRCA Mutation Carriers
NCT01608074
Centre Oscar LambretN/A
Active Not RecruitingEndocrine Disruptors and Life STILe in Breast Cancer Development
NCT05748353
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Withdrawn3.0 Tesla Magnetic Resonance Imaging for Breast Cancer Detection in High Risk Women
NCT01409226
NYU Langone HealthN/A